Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
AssigneeYeda Research and Development Co. Ltd.
InventorsBilha Schechter, Ruth Arnon, Meir Wilchek
Life of this patent
Estimating the term…
Abstract
The present invention relates to avidin-type molecules having 2,4,6-trinitrophenyl or lactosyl groups or being complexed with an antibody specific to the avidin-type molecule, which shifts the biodistribution pattern in tissues and organs to the liver, where these molecules accumulate at high levels over several days. These modified avidin-type molecules provide a means for delivery of diagnostic and therapeutic agents, including radionuclides to the liver and cells of the reticuloendothelial system (RES) for diagnosing and treating hepatic disorders and disorders of the RES.
Claims38
An isolated modified avidin-type molecule, comprising an avidin-type molecule modified with a 2,4,6-trinitrophenyl (TNP) group or a lactosyl group at ε-amino groups of lysine residues for targeting said avidin-type molecule to the liver.
Dependencies are inferred from the claim text.